Causal pathways for CCR5 genotype and HIV progression

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 2, 2000, Pages 160-171

  Taylor, Jeremy M G ^a   Wang, Yan ^b   Ahdieh, Linda ^c   Chmiel, Joan S ^d   Detels, Roger ^b   Giorgi, Janis V ^b   Kaslow, Richard ^e   Kingsley, Lawrence ^f   Margolick, Joseph ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

AIDS; CCR5 heterozygosity; CD4+ T cells; HIV; Longitudinal modeling; Proportional hazards model; Viral load

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ARTICLE; DISEASE COURSE; GENE DELETION; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; STATISTICAL MODEL; VIRUS LOAD;

EID: 0034143777     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200002010-00008     Document Type: Article

References (29)

1. Clerici M, Giorgi JV, Chou CC, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992;165:1012-19.
2. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
3. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2:412-17.
4. Harden V, D'Souza P. Chemokines and HIV second receptors: a short history of a recent breakthrough. Nat Med 1996;12:1293-1300.
5. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;22:722-5.
6. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;3:367-77.
7. Dean M, Carrington M, Winkler C, et al. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study, O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
8. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
9. Eugen-Olsen J, Iversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997;11:305-10.
10. Meyer L, Magierowska M, Hubert JB, et al. and the SEROCO study group. Early protective effect of CCR5 Δ32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 1997;11:F73-84.
11. Misrahi M, Teglas JP, N'Go N, et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. JAMA 1998;279:277-80.
12. Huang Y, Paxton WA, Wolinzky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;11:1240-3.
13. + T cell number at the time of AIDS. Am J Epidemiol 1995;141:645-51.
14. + and declining CDS-populations suggest regulatory responses linked to loss of CD4 lymphocytes. J Acquir Immune Defic Syndr 1993;6:153-61.
15. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in Plasma Predicts Outcome after seroconversion. Ann Intern Med 1995;122:573-9.
16. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
17. Albert JM, Ioannidis JPA, Reichelderfer B, et al. Statistical issues for HIV endpoints: point/counterpoint. Stat Med 1998;17:2435-62.
18. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997;277:959-65.
19. + cell count and rate of progression to AIDS following acute HIV-1 infection. AIDS 1998;12:2107-13.
20. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-52.
21. Ho DD. Viral counts count in HIV infection. Science 1996;272: 1124-5.
22. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study: rationale, organization and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-18.
23. Taylor JMG, Wang Y. Jointly modeling longitudinal and survival data. In: Payne R, Green P. Proceedings in computational statistics. New York: Springer-Verlag, 1998:467-472.
24. Taylor JMG, Cumberland WG, Sy JP. A stochastic model for analysis of longitudinal AIDS data. J Am Stat Assoc 1994;89:727-36.
25. LaValley MP, DeGruttola V. Models for empirical Bayes estimators of longitudinal CD4 counts. Stat Med 1996;15:2289-2305.
26. Wang Y, Taylor JMG. Jointly modeling longitudinal and event time data: application in AIDS studies. Technical report. 1999.
27. Faucett CL, Thomas DC. Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. Stat Med 1996;15:1663-85.
28. Prentice RL. Covariate measurement errors and parameter estimation in a failure time regression model Biometrika 1982;69:331-42.
29. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1infection. Ann Intern Med 1997;127:882-90.